Glaxo Bid Undervalues Human Genome Sciences, Sunday Times Says

GlaxoSmithKline Plc (GSK)’s $2.6 billion offer for Human Genome Sciences Inc. (HGSI) “completely undervalues” the company according to a major shareholder, the Sunday Times reported.

Mark Evans from Taube Hodson Stonex Partners LLP, a fund manager that owns 5.6 percent of the U.S. drugs maker, termed the bid “unacceptable,” the London-based newspaper said.

Human Genome rejected Glaxo’s $13-a-share cash offer on April 19.

To contact the reporter on this story: Lucy Meakin in London at lmeakin1@bloomberg.net

To contact the editor responsible for this story: Daniel Tilles at dtilles@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.